Do statins delay the incidence of ESRD in diabetic patients with moderate CKD?

Journal of Nephrology

Volumn 23, Issue 3, 2010, Pages 321-327

  Conley, James ^a   Olafsson, Andrew ^a   Djamali, Arjang ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

CKD; Egfr; ESRD; Progression; Statins

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUINDOSTATIN; GLITAZONE DERIVATIVE; HEMOGLOBIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; SULFONYLUREA; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE COURSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GLOMERULUS FILTRATION RATE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PREDICTION; PROTEINURIA; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL;

ADULT; CHOLESTEROL, LDL; CHRONIC DISEASE; DIABETES COMPLICATIONS; DISEASE PROGRESSION; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 77951735201     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003;41:1-12. (Pubitemid 36043346)
2. Banes-Berceli AK, Shaw S, Ma G, et al. Effect of simvastatin on high glucose- and angiotensin II-induced activation of the JAK/STAT pathway in mesangial cells. Am J Physiol Renal Physiol. 2006;291:F116-F121. (Pubitemid 43945941)
3. Chen HC, Guh JY, Shin SJ, Lai YH. Pravastatin suppress superoxide and fibronectin production of glomerular mesangial cells induced by oxidized-LDL and high glucose. Atherosclerosis. 2002;160:141-146. (Pubitemid 34082719)
4. Danesh FR, Sadeghi MM, Amro N, et al. 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/ p21 signaling pathway: Implications for diabetic nephropathy. Proc Natl Acad Sci USA 2002;99:8301-8305. (Pubitemid 34651047)
5. Kim SI, Han DC, Lee HB. Lovastatin inhibits transforming growth factor-beta1 expression in diabetic rat glomeruli and cultured rat mesangial cells. J Am Soc Nephrol 2000;11:80-87. (Pubitemid 30020429)
6. Ota T, Takamura T, Ando H, Nohara E, Yamashita H, Kobayashi K. Preventive effect of cerivastatin on diabetic nephropathy through suppression of glomerular macrophage recruitment in a rat model. Diabetologia. 2003;46:843-851. (Pubitemid 36831414)
7. Usui H, Shikata K, Matsuda M, et al. HMG-CoA reductase inhibitor ameliorates diabetic nephropathy by its pleiotropic effects in rats. Nephrol Dial Transplant. 2003;18:265-272. (Pubitemid 36181675)
8. Yokota T, Utsunomiya K, Murakawa Y, Kurata H, Tajima N. Mechanism of preventive effect of HMG-CoA reductase inhibitor on diabetic nephropathy. Kidney Int Suppl 1999;71:S178-81. (Pubitemid 29304846)
9. Zeng L, Xu H, Chew TL, et al. HMG CoA reductase inhibition modulates VEGF-induced endothelial cell hyperpermeability by preventing RhoA activation and myosin regulatory light chain phosphorylation. FASEB J. 2005;19:1845-1847. (Pubitemid 41598770)
10. Zhu B, Shen H, Zhou J, Lin F, Hu Y. Effects of simvastatin on oxidative stress in streptozotocin-induced diabetic rats: a role for glomeruli protection. Nephron Exp Nephrol 2005;101:e1-e8. (Pubitemid 41159945)
11. Sandhu S, Wiebe N, Fried LF, Tonelli M. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol 2006;17:2006-2016. (Pubitemid 44036185)
12. Douglas K, O'Malley PG, Jackson JL. Meta-analysis: the effect of statins on albuminuria. Ann Intern Med 2006;145:117-124.
13. Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006;145:247-254. (Pubitemid 46768608)
14. Hommel E, Andersen P, Gall MA, et al. Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy. Diabetologia. 1992;35:447-451.
15. Lam KS, Cheng IK, Janus ED, Pang RW. Cholesterol-lowering therapy may retard the progression of diabetic nephropathy. Diabetologia 1995;38:604-609.
16. Nakamura T, Ushiyama C, Hirokawa K, Osada S, Shimada N, Koide H. Effect of cerivastatin on urinary albumin excretion and plasma endothelin-1 concentrations in type 2 diabetes patients with microalbuminuria and dyslipidemia. Am J Nephrol 2001;21:449-454. (Pubitemid 34088200)
17. Nielsen S, Schmitz O, Moller N, et al. Renal function and insulin sensitivity during simvastatin treatment in type 2 (noninsulin-dependent) diabetic patients with microalbuminuria. Diabetologia. 1993;36:1079-1086. (Pubitemid 23288779)
18. Tonolo G, Ciccarese M, Brizzi P, et al. Reduction of albumin excretion rate in normotensive microalbuminuric type 2 diabetic patients during long-term simvastatin treatment. Diabetes Care. 1997;20:1891-1895. (Pubitemid 27522902)
19. Zhang A, Vertommen J, Van GL, De LI. Effects of pravastatin on lipid levels, in vitro oxidizability of non-HDL lipoproteins and microalbuminuria in IDDM patients. Diabetes Res Clin Pract. 1995;29:189-194.
20. Verhulst A, D'Haese PC, De Broe ME. Inhibitors of HMGCoA reductase reduce receptor-mediated endocytosis in human kidney proximal tubular cells. J Am Soc Nephrol. 2004;15:2249-2257. (Pubitemid 39159325)
21. Wen M, Segerer S, Dantas M, et al. Renal injury in apolipoprotein E-deficient mice. Lab Invest. 2002;82:999-1006.
22. Kasiske BL, O'Donnell MP, Schmitz PG, Kim Y, Keane WF. Renal injury of diet-induced hypercholesterolemia in rats. Kidney Int 1990;37:880-891. (Pubitemid 20089220)
23. Gervais M, Pons S, Nicoletti A, Cosson C, Giudicelli JF, Richer C. Fluvastatin prevents renal dysfunction and vascular NO deficit in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2003;23:183-189. (Pubitemid 36231926)